Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Generic Injectables Market Research Report 2026 - Revenue to Reach $285.61 Billion by 2031, Driven by Patent Expirations and Biosimilar Growth

globenewswire.com
PFE Pfizer Inc. is mentioned as a company profile in the report. While the article focuses on the generic injectables market, Pfizer's inclusion indicates its presence, but no specific sentiment is expressed towards the company. BIIB Biogen Inc. is not explicitly mentioned in the article. While the article discusses biosimilars and large-molecule injectables, Biogen is not listed among the company profiles or mentioned directly. AMGN Amgen Inc. is not explicitly mentioned in the article. The article discusses biosimilars and large-molecule injectables, but Amgen is not listed among the company profiles or mentioned directly. REGN Regeneron Pharmaceuticals, Inc. is not explicitly mentioned in the article. The article discusses biosimilars and large-molecule injectables, but Regeneron is not listed among the company profiles or mentioned directly. BMY Bristol Myers Squibb Company is not explicitly mentioned in the article. The article discusses the generic injectables market, but Bristol Myers Squibb is not listed among the company profiles or mentioned directly. GILD Gilead Sciences, Inc. is not explicitly mentioned in the article. The article discusses the generic injectables market, but Gilead Sciences is not listed among the company profiles or mentioned directly. ABBV AbbVie Inc. is not explicitly mentioned in the article. The article discusses the generic injectables market, but AbbVie is not listed among the company profiles or mentioned directly. MRK Merck & Co., Inc. is not explicitly mentioned in the article. The article discusses the generic injectables market, but Merck is not listed among the company profiles or mentioned directly. JNJ Johnson & Johnson is not explicitly mentioned in the article. The article discusses the generic injectables market, but Johnson & Johnson is not listed among the company profiles or mentioned directly. BAX Baxter International Inc. is listed as a company profile in the report, which analyzes the generic injectables market. The article does not provide specific sentiment for Baxter, but its inclusion suggests it is a player in this growing market. VTRS Viatris Inc. is listed as a company profile in the report, which analyzes the generic injectables market. The article does not provide specific sentiment for Viatris, but its inclusion suggests it is a player in this growing market.

Generic Injectables Market Research Report 2026 - Revenue to Reach $285.61 Billion by 2031, Driven by Patent Expirations and Biosimilar Growth Dublin, Aug. 18, 2026 (GLOBE NEWSWIRE) -- The "Generic Injectables - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

The global generic injectables market was valued at USD 131.68 billion in 2025 and is projected to increase from USD 149.82 billion in 2026 to USD 285.61 billion by 2031. The market is expected to register a compound annual growth rate of 13.77% during the 2026-2031 forecast period.

Market growth is supported by branded injectable patent expirations, rising demand for affordable oncology and anti-infective therapies, expanding biosimilar approvals, and growing hospital adoption of ready-to-use formats. The report analyzes the market by product type, molecule type, therapeutic area, route of administration, distribution channel, and geography, with forecasts provided in USD.

Patent Expirations Accelerate Generic Injectable Launches

A broad wave of injectable drug exclusivity losses is creating opportunities for abbreviated approvals and faster portfolio expansion. The impact is particularly significant in oncology, supportive care, and acute care, where hospitals require clinically appropriate alternatives as branded products lose patent protection.

The U.S. Food and Drug Administration approved four first generic injectable drugs during the first quarter of 2026, including bortezomib powder for injection and aprepitant injection. These approvals demonstrate continued regulatory activity across sterile drug categories. High technical and regulatory barriers may also limit the number of qualified competitors, supporting more durable demand for early market entrants with compliant manufacturing capacity.

Oncology and Anti-Infective Demand Supports Market Expansion

Oncology accounted for 33.26% of generic injectables market revenue in 2025 and is forecast to grow at a CAGR of 16.55% through 2031. Demand is rising for cost-effective injectable cancer therapies that meet stringent quality, availability, and supply continuity requirements.

Anti-infective injectables also remain essential across hospital settings, including carbapenems, beta-lactams, antifungals, and other acute care treatments. Procurement strategies increasingly consider manufacturing quality, supplier diversity, and replenishment reliability alongside pricing. This trend benefits manufacturers that can provide consistent supply in clinically sensitive and shortage-prone categories.

Sterile Fill-Finish Capacity Remains a Key Constraint

Limited sterile fill-finish capacity continues to restrict the commercialization of generic injectable products. Aseptic manufacturing requires specialized equipment, extensive validation, and longer production ramp-up periods. According to a 2024 Parenteral Drug Association survey concerning EU GMP Annex 1 implementation, 40% of responding facilities required timeline extensions, while 30% reported upgrade investments exceeding USD 2 million.

These requirements may create scheduling, validation, and regulatory bottlenecks when product launches, shortage responses, and facility upgrades occur simultaneously. Manufacturers with approved products may therefore face delays in converting regulatory clearances into dependable commercial supply.

Additional market factors include:

Product and Molecule Segment Insights

Vials represented 45.31% of market revenue in 2025, reflecting their established use in oncology infusion, anti-infective treatment, and institutional care. Prefilled syringes are forecast to grow at a CAGR of 16.38% through 2031 as healthcare providers seek fewer preparation steps, safer handling, and greater compatibility with subcutaneous therapies.

The positive June 2026 Committee for Medicinal Products for Human Use opinion for Nylaspeg, a pegfilgrastim biosimilar supplied in a 6 mg prefilled syringe, reflects the increasing integration of ready-to-use delivery formats into biosimilar launches. Ampoules retain demand in anesthesia and emergency medicine, while IV bags and large-volume parenterals remain important in critical care, electrolyte replacement, and parenteral nutrition. Cartridges support insulin and GLP-1 delivery systems where device compatibility is a central requirement.

Small-molecule generics held 58.24% of the generic injectables market in 2025. This segment includes IV antibiotics, cytotoxic chemotherapy, analgesics, and cardiovascular injectables. Large-molecule injectables and biosimilar generics are projected to expand at a CAGR of 15.52% through 2031, supported by growing investment in biologic development, analytical capabilities, and sterile manufacturing.

The FDA approved 18 injectable biosimilars in 2025, bringing the total number of approved biosimilars to 90 as of early 2026. In June 2026, Aurobindo Pharma launched the TheraNym biologics contract manufacturing facility in Telangana, featuring 15-kiloliter bioreactors and aseptic fill-finish capabilities. Such investments illustrate the industry's shift toward complex, higher-value injectable products.

Regional Generic Injectables Market Outlook

North America held 36.78% of global market revenue in 2024, supported by advanced hospital infrastructure, established regulatory pathways, automated compounding systems, and growing adoption of ready-to-administer products. Healthcare systems are investing in technologies and delivery formats designed to reduce medication errors and clinical workloads.

Asia-Pacific is expected to record the fastest regional growth, with a projected CAGR of 16.43%. India's Production Linked Incentive program is directing approximately USD 2 billion toward sterile manufacturing capacity and technology upgrades. China's increasing alignment with International Council for Harmonisation guidelines is also strengthening export credibility. Japan, South Korea, and Australia contribute through biosimilar adoption and supportive pricing frameworks.

Europe remains an important market due to its established pharmaceutical manufacturing base, broad patient access, and stringent quality requirements. Revised EU GMP Annex 1 requirements are increasing compliance costs while encouraging stronger contamination-control and supply-reliability standards. Germany and France lead regional adoption of automated fill-finish systems, while Eastern Europe continues to attract contract manufacturing investment.

Key Topics Covered

1 Introduction

1.1 Study Assumptions & Market Definition

1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

4.1 Market Overview

4.2 Market Drivers

4.2.1 Patent Cliff Wave Accelerating Generic Launches

4.2.2 Rising Demand for Sterile Affordable Oncology and Anti-Infective Therapies

4.2.3 Hospital Preference for Ready-to-Use and Pre-Administration Formats

4.2.4 Biosimilar and Complex Injectable Approvals Broadening Addressable Demand

4.2.5 AI-Assisted Formulation and Analytical Development Shortening Development Cycles

4.2.6 Lyophilized-to-Liquid Conversion Lowering Cold-Chain and COGS Burden

4.3 Market Restraints

4.3.1 Sterile Fill-Finish Capacity Bottlenecks

4.3.2 Tender-Led Price Compression and GPO Consolidation

4.3.3 Annex 1 and Sterility Compliance Cost Escalation

4.3.4 Volatile Supply of Type I Glass and COP Components

4.4 Supply Chain Analysis

4.5 Regulatory Landscape

4.6 Technological Outlook

4.7 Porter's Five Forces Analysis

4.7.1 Bargaining Power of Suppliers

4.7.2 Bargaining Power of Buyers

4.7.3 Threat of New Entrants

4.7.4 Threat of Substitutes

4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts (Value, USD)

5.1 By Product Type

5.1.1 Vials

5.1.2 Ampoules

5.1.3 Prefilled Syringes

5.1.4 Cartridges

5.1.5 IV Bags and Large Volume Parenterals

5.2 By Molecule Type

5.2.1 Small-Molecule Generics

5.2.2 Large-Molecule Injectables and Biosimilar Generics

5.3 By Therapeutic Area

5.3.1 Oncology

5.3.2 Anti-Infectives

5.3.3 Cardiovascular

5.3.4 Diabetes and Metabolic Disorders

5.3.5 Central Nervous System Disorders

5.3.6 Other Therapeutic Areas

5.4 By Route of Administration

5.4.1 Intravenous

5.4.2 Intramuscular

5.4.3 Subcutaneous

5.4.4 Other Routes of Administration

5.5 By Distribution Channel

5.5.1 Hospital Pharmacies

5.5.2 Retail and Mail-Order Pharmacies

5.5.3 Online Pharmacies

5.5.4 Other Distribution Channel

5.6 By Geography

5.6.1 North America

5.6.1.1 United States

5.6.1.2 Canada

5.6.1.3 Mexico

5.6.2 Europe

5.6.2.1 Germany

5.6.2.2 United Kingdom

5.6.2.3 France

5.6.2.4 Italy

5.6.2.5 Spain

5.6.2.6 Rest of Europe

5.6.3 Asia-Pacific

5.6.3.1 China

5.6.3.2 Japan

5.6.3.3 India

5.6.3.4 Australia

5.6.3.5 South Korea

5.6.3.6 Rest of Asia-Pacific

5.6.4 Middle East and Africa

5.6.4.1 GCC

5.6.4.2 South Africa

5.6.4.3 Rest of Middle East and Africa

5.6.5 South America

5.6.5.1 Brazil

5.6.5.2 Argentina

5.6.5.3 Rest of South America

6 Competitive Landscape

6.1 Market Concentration

6.2 Market Share Analysis

6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)

6.3.1 Accord Healthcare Limited

6.3.2 Apotex Inc.

6.3.3 Aurobindo Pharma Limited

6.3.4 Baxter International Inc.

6.3.5 Cipla Ltd.

6.3.6 Dr. Reddy's Laboratories Ltd.

6.3.7 Endo International plc

6.3.8 Fresenius Kabi

6.3.9 Glenmark Pharmaceuticals Ltd.

6.3.10 Hikma Pharmaceuticals PLC

6.3.11 Intas Pharmaceuticals Ltd.

6.3.12 Lupin Limited

6.3.13 Pfizer Inc.

6.3.14 Sandoz Group AG

6.3.15 Sawai Pharmaceutical Group

6.3.16 STADA Arzneimittel AG

6.3.17 Sun Pharmaceutical Industries Ltd.

6.3.18 Teva Pharmaceutical Industries Ltd.

6.3.19 Viatris Inc.

6.3.20 Zydus Lifesciences Limited

7 Market Opportunities & Future Outlook

7.1 White-Space and Unmet-Need Assessment

For more information about this report visit https://www.researchandmarkets.com/r/gm3eo3

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.